title: Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting.
abstract: BACKGROUND
  Hepatitis C virus (HCV) infection represents serious health problems worldwide and is a major contributor to end-stage liver disease including cirrhosis and hepatocellular carcinoma (HCC). In Italy, ~2% of subjects are infected with HCV. The objective of this study was to describe treatment patterns, disease progression, and resource use in HCV.
  
  
  METHODS
  An observational retrospective cohort analysis based on four Local Health Units administrative and laboratory databases was conducted. HCV-positive patients between January 1, 2009 and December 31, 2010 were included and followed-up for 1 year. To explore which covariates were associated to disease progression (cirrhosis, HCC, death for any cause), Cox proportional hazards models were performed.
  
  
  RESULTS
  A total of 9,514 patients were analyzed of which 55.6% were male, aged 58.1±16.1, and prevalence 0.4%; 5.8% were positive to human immunodeficiency virus (HIV) infection, 3.0% to hepatitis B virus (HBV), and 1.6% to HCV+HBV+HIV; 26.1% had cirrhosis and 4.3% HCC. The majority of patients (76%) did not receive an antiviral treatment; the main factors affecting this decision were age, 44.1% of untreated patients being aged >65 years; 31% were affected by cirrhosis, 6.6% had ongoing substance or alcohol abuse, and 5.5% were affected by HCC. Disease progression in the observed timeframe was less frequent among treated patients (incidence rate per 100 patients/year: cirrhosis 2.1±0.7 vs 13.0±1.0, HCC 0.5±0.3 vs 3.6±0.5, death 0.5±0.3 vs 6.4±0.7). The annual expenditure for HCV management (drugs, hospitalizations, outpatient services) was €4,700 per patient.
  
  
  CONCLUSIONS
  This observational, real-life study shows that only a small proportion of patients received antiviral therapy in the territorial services investigated; among patients who were not treated, this is reflected in a disease progression and cost of management higher than treated patients. These results suggest the importance of better defining the categories of patients who can really postpone treatment, and those who require immediate antiviral therapy.
authors: CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna, Italy.
authors: Valentina
authors: V
authors: Perrone
authors: CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna, Italy.
authors: Diego
authors: D
authors: Sangiorgi
authors: CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna, Italy.
authors: Stefano
authors: S
authors: Buda
authors: CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna, Italy.
authors: Luca
authors: L
authors: Degli Esposti
keywords: HCC; HCV; cirrhosis; cost of illness; hepatitis C virus; hepatocellular carcinoma; real practice